ALL-20249 Juvedermit folder

Page 1

HIGH PATIENT SATISFACTION 2

IT’S TIME TO SCULPT IT

94% (N=85) of patients reported satisfaction improvement from baseline with their chin at 3 months after Juvéderm® VOLUX treatment.2,*

1

For illustrative purposes only.

The majority of injection site responses were mild to moderate in severity and generally resolved within 1 week after treatment.7

months

The latest injectable gel in the VYCROSS® collection,1 part of the world’s number one brand of hyaluronic acid (HA) facial fillers8,*

Restores and creates facial volume, allowing you to improve the G-Sn-Pog angle and chin projection2

May give patients and physicians visible, lasting and satisfactory results for 18–24 months2,5,†

* Based on healthcare professional (HCP) tracking market research, from over 1000 HCPs in the largest 13 aesthetic markets worldwide. 8 † Based on comparative preclinical in vitro testing and results from repeat treatment data, added to Juvéderm® VOLUX clinical study showing duration beyond 18 months after initial treatment or initial + top-up treatment in the chin and jaw, as well as clinical results for predicate device Juvéderm® VOLUMA with lidocaine showing 24 month duration in the mid-face established Juvéderm® VOLUX as having an in situ duration of 18–24 months. 4

1. Juvéderm® VOLUX DFU. 72778JR10. Revision 2018-07-26. 2. Allergan. Data on File. INT/0654/2018. Juvéderm® VOLUX final clinical study report & clinical evaluation report – efficacy and duration data. Oct 2018. 3. Ogilvie P et al. Poster Presentation at Aesthetic & Anti-Aging Medicine World Congress (AMWC), Monte Carlo, Monaco; 2018. 4. Raspaldo H et al. J Cosmet Dermatol. 2010;9:11–15. 5. Allergan. Data on File. INT/0074/2019. Juvéderm® VOLUX final clinical evaluation report, July 2018. Jan 2019. 6. Allergan. Data on File. INT/0663/2018. Juvéderm® VOLUX final clinical evaluation report. Oct 2018. 7. Allergan. Data on File. INT/0661/2018. Juvéderm® VOLUX final clinical study report – safety data. Oct 2018. 8. Allergan. Unpublished Data. INT/0771/2016(2). JUVÉDERM ®, the world’s leading brand of hyaluronic acid facial fillers. Feb 2019. Allergan Norden AB, Strandbergsgatan 61, 112 51 Stockholm, Sverige To report Adverse Events please contact: ProductSurveillance_EAME@Allergan.com

N = total sample number. * Additional effectiveness analyses: patients reporting improvement from baseline on 3 modules of the FACE-Q questionnaire (Satisfaction with Chin, Satisfaction with Lower Face and Jawline, and Psychological Well-being). 2

with Juvéderm® VOLUX 1,*

WWW.JUVEDERM.SE

JUVEDERMSE

JUVEDERMSE

WWW.JUVEDERM.DK

JUVEDERMDK

JUVEDERMDK

WWW.JUVEDERM.NO

JUVEDERMNO

JUVEDERMNO

WWW.JUVEDERM.FI

JUVEDERMFI

JUVEDERMFI

ND/0219/2019. Date of preparation: May 2019.

94%

18–24

When you want to define the lower face1–3,† Model treated with JUVÉDERM ®. Results may vary. Juvéderm ® VOLUX is an injectable implant intended to restore and create volume of the face.1 * Juvéderm ® VOLUX contains lidocaine.1 The addition of lidocaine does not alter the product’s physical properties. 4 † Clinical study assessed lower face as chin and jaw area. 2


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.
ALL-20249 Juvedermit folder by Billes - Issuu